---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-004092"
form_type: "8-K"
ticker: "VIR"
cik: "0001706431"
company_name: "Vir Biotechnology, Inc."
filed_at: "2023-02-23T23:59:59+00:00"
generated_at: "2026-06-19T02:58:52.181166+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vir Biotech Q4 net loss $101.6M; CEO Scangos retiring, CFO Horn resigning

## Summary
- Q4 2022 revenue $49.4M vs $812.7M YoY; net loss $0.76/share vs net income $4.01/share.
- Full year 2022 revenue $1.6B, net income $515.8M ($3.89/share); cash & investments ~$2.4B.
- CEO George Scangos retiring April 3, 2023; succeeded by Marianne De Backer (Bayer exec).
- CFO Howard Horn resigning; replaced by Sung Lee, 20-year biotech veteran.
- Key pipeline catalysts: HBV data H1 2023, influenza PENINSULA data mid-2023, HDV data H2 2023.

## SEC filing metadata
- accession: 0000950170-23-004092
- form_type: 8-K
- ticker: VIR
- cik: 0001706431
- company_name: Vir Biotechnology, Inc.
- filed_at: 2023-02-23T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1706431/000095017023004092/0000950170-23-004092-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1706431/000095017023004092/vir-20230223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-004092
- JSON: https://secwatch.observer/filing/0000950170-23-004092.json
- Plain text: https://secwatch.observer/filing/0000950170-23-004092.txt

## Key facts
- Earnings Releases
  Vir Biotechnology, Inc. reported financial results for the fourth quarter ended December 31, 2022.
  - Period: the fourth quarter ended December 31, 2022
  - Result: reported results
  source text: Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1706431/000095017023004092/0000950170-23-004092-index.htm
- Earnings Releases
  Vir Biotechnology, Inc. reported the full year ended December 31, 2022 results: revenue $1.5 billion.
  - Period: the full year ended December 31, 2022
  - Revenue: $1.5 billion
  - Result: reported results
  source text: – $1.5 billion of sotrovimab collaboration revenue recognized in 2022 –
  evidence_url: https://www.sec.gov/Archives/edgar/data/1706431/000095017023004092/0000950170-23-004092-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.